[go: up one dir, main page]

CR8990A - Produccion de policetidos y otros productos naturales - Google Patents

Produccion de policetidos y otros productos naturales

Info

Publication number
CR8990A
CR8990A CR8990A CR8990A CR8990A CR 8990 A CR8990 A CR 8990A CR 8990 A CR8990 A CR 8990A CR 8990 A CR8990 A CR 8990A CR 8990 A CR8990 A CR 8990A
Authority
CR
Costa Rica
Prior art keywords
production
natural products
policetides
compounds
desmethylrapamycin
Prior art date
Application number
CR8990A
Other languages
English (en)
Inventor
Mathew Alan Gregory
Original Assignee
Biotica Tecnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tecnology Ltd filed Critical Biotica Tecnology Ltd
Publication of CR8990A publication Critical patent/CR8990A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a la produccion de policetidos y otros productos naturales y a genotecas de compuestos y a compuestos novedosos individuales. Provee 17-desmetilrapamicina y analogos de la misma, metodos para su produccion incluyendo cepas recombinantes, y aislamiento y usos de los compuestos de la invencion.
CR8990A 2004-08-11 2007-03-12 Produccion de policetidos y otros productos naturales CR8990A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417852.1A GB0417852D0 (en) 2004-08-11 2004-08-11 Production of polyketides and other natural products

Publications (1)

Publication Number Publication Date
CR8990A true CR8990A (es) 2009-01-14

Family

ID=33017292

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8990A CR8990A (es) 2004-08-11 2007-03-12 Produccion de policetidos y otros productos naturales

Country Status (19)

Country Link
US (1) US7803808B2 (es)
EP (2) EP2471797B1 (es)
JP (1) JP2008509895A (es)
KR (1) KR20070052784A (es)
CN (2) CN101805748A (es)
AU (1) AU2005270989B2 (es)
BR (1) BRPI0514236A (es)
CA (1) CA2575582A1 (es)
CR (1) CR8990A (es)
EC (1) ECSP077303A (es)
GB (1) GB0417852D0 (es)
IL (1) IL181171A0 (es)
MX (1) MX2007001809A (es)
NO (1) NO20070686L (es)
NZ (1) NZ553074A (es)
RU (2) RU2430922C2 (es)
UA (1) UA95895C2 (es)
WO (1) WO2006016167A2 (es)
ZA (1) ZA200701622B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534442A (ja) * 2005-03-11 2008-08-28 バイオティカ テクノロジー リミテッド 化合物の用途
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
CA2599547A1 (en) * 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
EP2029147B1 (en) * 2006-06-12 2010-05-19 Ramot at Tel-Aviv University Ltd. Methods for treating cancer
US8063075B2 (en) 2008-06-10 2011-11-22 Hoffmann-La Roche Inc. Pyrrolidine ether derivatives as NK3 receptor antagonists
CA3069819C (en) 2010-11-30 2022-07-26 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2014100742A2 (en) 2012-12-21 2014-06-26 The Regents Of The University Of California Modulation of expression of acyltransferases to modify hydroxycinnamic acid content
GB201312318D0 (en) 2013-07-09 2013-08-21 Isomerase Therapeutics Ltd Novel methods and compounds
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
JP7104627B2 (ja) 2016-02-04 2022-07-21 ザ・ジョンズ・ホプキンス・ユニバーシティ ラパグルチン（ｒａｐａｇｌｕｔｉｎｓ）、ｇｌｕｔの新規阻害剤及びその使用
CA3013650A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US10662220B2 (en) 2016-02-04 2020-05-26 The Johns Hopkins University Synthesis and composition of rapafucin libraries
SG11201908226XA (en) * 2017-02-10 2019-10-30 Mount Tam Therapeutics Inc Rapamycin analog
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
CN107629994B (zh) * 2017-10-25 2021-11-02 中国科学院上海有机化学研究所 一种构建fk520高产工程菌株的方法和吸水链霉菌高产菌株
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
CN109467579B (zh) * 2018-11-01 2021-10-15 海南大学 一种具有免疫抑制活性的pks i型聚酮类化合物及其制备方法和应用
CN110627702B (zh) * 2019-10-18 2022-11-15 福建师范大学 聚酮化合物及其制备方法和用途
EP3854350A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of manufacturing an endoprosthesis
EP3854349A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of manufacturing an endoprosthesis
EP3854348A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of attaching a fiber to a surface
CN115125179B (zh) * 2021-03-26 2023-10-27 上海医药工业研究院 产雷帕霉素的基因工程菌及其应用
US20230104503A1 (en) * 2021-06-25 2023-04-06 The Regents Of The University Of California Small molecule compounds
KR102774027B1 (ko) * 2021-12-09 2025-02-27 국립낙동강생물자원관 항암, 항적조 및 항염증 활성을 가지는 민물해면 분리 마이크로모노스포라 속 ms-62 균주 및 이의 용도
CN118324775B (zh) * 2024-03-01 2025-03-21 中山大学附属第五医院 一种聚酮化合物及其在制备抗肺纤维化的药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993479A (en) 1975-08-04 1976-11-23 Olin Corporation Copper base alloy
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5109112A (en) 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
CA2102116A1 (en) 1991-05-31 1992-12-01 Gary R. Schulte Use of rapamycin prodrugs as immunosuppressant agents
US5763590A (en) 1991-10-11 1998-06-09 Vertex Pharmaceuticals, Inc. Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA
US5498597A (en) 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5354845A (en) 1993-04-21 1994-10-11 Children's Research Institute FK-506 and rapamycin specific binding immunophilin
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
PT734389E (pt) 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9710962D0 (en) 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
GEP20012348B (en) 1996-07-05 2001-01-25 Pfizer Erythromycins and Process for Their Preparation
DE69736750T2 (de) 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9814006D0 (en) 1998-06-29 1998-08-26 Biotica Tech Ltd Polyketides and their synthesis
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
AU777997B2 (en) 1999-07-09 2004-11-11 Oregon Health And Science University Compositions and methods for promoting nerve regeneration
EP1212331B1 (en) * 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU2748701A (en) 1999-10-29 2001-06-06 Kosan Biosciences, Inc. Rapamycin analogs
ES2338212T3 (es) 2000-04-13 2010-05-05 Biotica Technology Limited Productos hibridos glicosilados y su produccion y utilizacion.
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
GB0019986D0 (en) 2000-08-14 2000-10-04 Biotica Tech Ltd Polyketides and their synthesis
GB0125043D0 (en) 2001-10-17 2001-12-12 Biotica Tech Ltd Production, detection and use of transformant cells
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
DK1492404T3 (da) 2002-02-19 2012-04-23 Dow Agrosciences Llc Nye spinosyndannende polyketidsyntaser
US7300942B2 (en) 2002-07-16 2007-11-27 Biotica Technology Limited Production of polyketides and other natural products

Also Published As

Publication number Publication date
NZ553074A (en) 2011-01-28
EP2471797A2 (en) 2012-07-04
UA95895C2 (ru) 2011-09-26
JP2008509895A (ja) 2008-04-03
WO2006016167A3 (en) 2006-04-13
AU2005270989B2 (en) 2012-04-05
WO2006016167A2 (en) 2006-02-16
CN101056880A (zh) 2007-10-17
KR20070052784A (ko) 2007-05-22
US20090253732A1 (en) 2009-10-08
ECSP077303A (es) 2007-04-26
EP2471797B1 (en) 2016-02-03
CN101805748A (zh) 2010-08-18
US7803808B2 (en) 2010-09-28
AU2005270989A1 (en) 2006-02-16
MX2007001809A (es) 2007-10-08
CA2575582A1 (en) 2006-02-16
RU2430922C2 (ru) 2011-10-10
NO20070686L (no) 2007-04-25
RU2007108772A (ru) 2008-09-20
GB0417852D0 (en) 2004-09-15
EP2029611A2 (en) 2009-03-04
EP2471797A3 (en) 2012-10-17
IL181171A0 (en) 2007-07-04
RU2009140290A (ru) 2011-05-10
ZA200701622B (en) 2008-06-25
BRPI0514236A (pt) 2008-06-03

Similar Documents

Publication Publication Date Title
CR8990A (es) Produccion de policetidos y otros productos naturales
CR9354A (es) Productos de microcapsula de liberacion rapida
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
CY1109707T1 (el) Διαδικασια παρασκευης ασεναπινης και ενδιαμεσων προϊοντων που χρησιμοποιουνται στην εν λογω διαδικασια
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR9569A (es) Modificaciones cristalinas de la piraclostrobina
CY1109088T1 (el) Μεθοδος για την παρασκευη υποκατεστημενων ενωσεων 3-αρυλο-βουτυλ-αμινης
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
CO6511201A2 (es) Anticuerpos anti-cdcp1 humanizados
UY28745A1 (es) Nuevos compuestos
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CU23415B7 (es) Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos
HN2006037713A (es) Compuestos utiles en terapia
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
CR9670A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
DK1670778T3 (da) Omlejrede pentanoler, en fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelsehæmmende
NI200700118A (es) Procedimientos para la preparacion de compuestos de quinolina y productos obtenidos de los mismos
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
CR9885A (es) Metodos para preparar derivados de acido glutamico
GT200600144AA (es) 1h-quinazolin-2,4-dionas (solicitud fraccionaria, derivada de la solicitud de patente de invencion pi-2006-00144)

Legal Events

Date Code Title Description
FC Refusal